scholarly journals Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera

2016 ◽  
Author(s):  
Eva Posfai
Keyword(s):  
Myocardial Infarction ◽  
Polycythemia Vera ◽  
Essential Thrombocythemia ◽  
Thrombotic Complication

Inherited Thrombophilias in Essential Thrombocythemia and Polycythemia Vera Are Not an Additional Risk Factor for Thrombosis.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4934-4934
Author(s):  
Emma Cacciola ◽  
Antonio Cipolla ◽  
Ernesto Di Francesco ◽  
Rosario Giustolisi ◽  
Rossella R. Cacciola
Keyword(s):  
Risk Factor ◽  
Polycythemia Vera ◽  
Essential Thrombocythemia ◽  
Thrombotic Complication ◽  
Additional Risk Factor ◽  
Clotting Factors ◽  
Platelet Factor ◽  
Thrombotic Risk ◽  
Additional Risk ◽  
Mthfr Mutation

Abstract Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have a high risk of thrombosis. Inherited thrombophilias are established risk factors for thrombosis. To determine if inherited thrombophilic abnormalities might contribute to the thrombotic risk in ET and PV, we investigated antitrombin III (ATIII), protein C (PC) and protein S (PS), polymorphisms of clotting factors V (FVQ506) and II (G20210A) and methylenetetrahydrofolate reductase (MTHFR) mutation in patients with ET and PV and we tried to correlate these results with prothrombotic markers such as bthromboglobulin (bTG), platelet factor 4 (PF4), prothrombin fragment 1+2 (F1+2) and d-dimer (DD). In addition, we analysed a possible association between inherited coagulopathy and thrombosis. ATIII, PC and PS antigen levels were assayed by ELISA as well as bTG, PF4 and F1+2. PCR-based assays were used for FVQ506, prothrombin and MTHFR. DD was measured by immunoturbimetric latex agglutination. The study involved 101 patients diagnosed with ET (71 patients, 30 men, 41 women, mean age 62.3 years) or PV (30 patients, 21 men, 9 women, mean age 65.4 years) according to conventional criteria. The duration of disease ranged between 1 to 12 years. Of 101 patients, 53 (52,47%) were non-carriers of mutations and among these 24 (45.28%) experienced thrombosis, 48 (47.52%) were carriers and 27 (56.25%) had thrombosis. With reference to carriers, 9/48 (14.58%) had combined mutations such as PC and PS (2/9), PS and G20210A (1/9), PC and MTHFR (4/9), G20210A and MTHFR (2/9). The prevalence of studied defects was 31.25% (15/48) and 18.75% (9/48) for deficiency of PC and PS, respectively, 8.33% (4/48) and 14.58% (7/48) for heterozygosity of FVQ502 and G20210A, respectively, and 45.83% (22/48) for MTHFR mutation. Deficiency of ATIII was not present. All patients had higher bTG, PF4 and F1+2 (365±654 IU/ml, 133±64 IU/ml and 2.6±2.5 nmol/L, respectively) than to controls (23.8±9.1 IU/ml, 5.5±2.8 IU/ml and 0.60.2 nmol/L, respectively) (p<0.0001) and normal DD (144±92 ng/L). No correlation between studied polymorphisms genetic and bTG, PF4, F1+2 and DD was found as well as with thrombotic complication. The frequency of thrombosis was not statistically different between non-carriers and carriers. Based on these data, it appears that inherited thrombophilias are not an additional risk factor for thrombosis in ET and PV and that the thrombotic phenomena are due to the abnormal platelet function that is part of the myeloproliferative disorders.

Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia

2011 ◽  
Vol 152 (45) ◽  
pp. 1795-1803 ◽  
Author(s):  
János László Iványi ◽  
Éva Marton ◽  
Márk Plander
Keyword(s):  
Polycythemia Vera ◽  
Essential Thrombocythemia ◽  
Philadelphia Chromosome ◽  
Janus Kinase ◽  
Thrombotic Complication ◽  
Idiopathic Myelofibrosis ◽  
Jak2 Mutation ◽  
Course Of Illness ◽  
Mutational Status ◽  
Outpatient Departments

In Philadelphia chromosome-negative chronic myeloproliferative neoplasia, i.e. polycythemia vera, essential thrombocythemia and primary idiopathic myelofibrosis enhanced risk of thrombosis could be connected with Janus kinase 2 gene mutation occurring in various frequency in these diseases (JAK2V617F). Since 2002 the presence of JAK2 mutation in chronic myeloproliferative neoplasia has been regularly detected. Aims: In a retrospective survey the possible connection between JAK2 mutation and thrombosis was analyzed in patients with chronic myeloproliferative neoplasia subgroups cared and treated in their hospital and outpatient departments. Patients and methods: Between 2007-2010 peripheral blood samples of 171 patients with chronic myeloproliferative neoplasia (68 patients of polycythemia vera, 84 of essential thrombocythemia and 19 ones with primary idiopathic myelofibrosis) were sent to several molecular biological laboratories, where V617F mutation from DNA specimens was detected by allele-specific polymerase chain reaction, as well. Thromboembolic complications (arterial, i.e. cerebro-and cardiovascular and venous thrombosis) occurred during course of illness of patients were registered. Statistical analysis was made by statistical software program for Windows. Results: JAK2 mutation in 53 patients with polycythemia vera (77.9%) was detected, whilst in essential thrombocythemia 55 patients (65.4%) and in primary idiopathic myelofibrosis 7 patients (36.8%) proved to be JAK2 positive. In 18 JAK2 positive patients of polycythemia vera thromboembolic episodes were observed (18/53, 33.9%), whilst in essential thrombocythemia JAK2 mutational status was accompanied with thromboembolic events in 17/55 patients (30.9%). In the 7 JAK2 positive ones with primary idiopathic myelofibrosis thrombotic complication did not occurred. However, in JAK2 negative cases thrombotic events could also be detected (from 10 JAK2 negative patients with polycythemia vera in four ones, and in six with JAK2 negative 23 essential thrombocythemic patients. Conclusions: Incidence of the JAK2 mutation in their patients with chronic myeloproliferative neoplasia subgroups mainly corresponds to the literary data. Thrombosis ensued both in JAK positive polycythemia vera and essential thrombocythemia cases occurred nearly in the same number, but the incidence of thrombosis ensued in JAK2 negative cases did not differ significantly from the JAK2 positive patients. From these results it could be suggested that the presence or absence of JAK2 mutation in the development of thrombosis has no predictive value in patients with chronic myeloproliferative neoplasia. Orv. Hetil., 2011, 152, 1795–1803.

Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

2020 ◽  
Author(s):  
Nicole Kucine ◽  
Shayla Bergmann ◽  
Spencer Krichevsky ◽  
Devin Jones ◽  
Michael Rytting ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Essential Thrombocythemia ◽  
Young Patients ◽  
Pegylated Interferon

scholarly journals Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Fulvia Pimpinelli ◽  
Francesco Marchesi ◽  
Giulia Piaggio ◽  
Diana Giannarelli ◽  
Elena Papa ◽  
...  
Keyword(s):  
Prospective Study ◽  
Polycythemia Vera ◽  
Essential Thrombocythemia ◽  
Active Treatment ◽  
Myeloproliferative Neoplasm ◽  
Large Prospective Study ◽  
Lower Response ◽  
Ongoing Treatment ◽  
Vaccine Immunogenicity

AbstractIn a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue.

Sign in / Sign up

Export Citation Format

Share Document